Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.8386
-0.0124 (-1.46%)
At close: Mar 28, 2025, 4:00 PM
0.8451
+0.0065 (0.78%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Coherus BioSciences Stock Forecast
CHRS's stock price has decreased by -65.35% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 5.38, with a low estimate of 1.50 and a high estimate of 7.00. The average target predicts an increase of 541.55% from the current stock price of 0.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coherus BioSciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +734.72% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +734.72% | Jan 23, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +615.48% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +734.72% | Dec 4, 2024 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +376.99% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
221.40M
from 266.96M
Decreased by -17.07%
Revenue Next Year
273.01M
from 221.40M
Increased by 23.31%
EPS This Year
-0.45
from 0.25
EPS Next Year
-0.33
from -0.45
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 328.7M | 384.7M | 357.0M | ||
| Avg | 221.4M | 273.0M | 339.2M | ||
| Low | 42.6M | 92.5M | 318.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.1% | 73.8% | 30.8% | ||
| Avg | -17.1% | 23.3% | 24.2% | ||
| Low | -84.0% | -58.2% | 16.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.22 | 0.07 | 0.44 | ||
| Avg | -0.45 | -0.33 | 0.22 | ||
| Low | -1.68 | -1.01 | 0.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -11.4% | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.